Third-generation anti-CD19 CAR T cells for relapsed/refractory chronic lymphocytic leukemia: a phase 1/2 study.

Autor: Derigs P; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany. Patrick.Derigs@med.uni-heidelberg.de., Schubert ML; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Dreger P; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Schmitt A; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Yousefian S; Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany., Haas S; Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany.; Heidelberg Institute for Stem Cell Technology and Experimental Medicine (HI-STEM gGmbH), Heidelberg, Germany.; Precision Healthcare University Research Institute, Queen Mary University of London, London, UK., Röthemeier C; Berlin Institute of Health (BIH) at Charité - Universitätsmedizin Berlin, Berlin, Germany.; Berlin Institute for Medical Systems Biology, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.; Department of Hematology, Oncology and Tumor Immunology, Charité University Medicine, Berlin, Germany., Neuber B; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Hückelhoven-Krauss A; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Brüggemann M; Department of Internal Medicine II, University Hospital Schleswig-Holstein, Kiel, Germany., Bernhard H; Department of Internal Medicine V, Klinikum Darmstadt, Darmstadt, Germany., Kobbe G; Department of Hematology, Oncology and Clinical Immunology, University Hospital Düsseldorf, Düsseldorf, Germany., Lindemann A; Onkologie in Ettlingen, Ettlingen, Germany., Rummel M; Department of Internal Medicine IV, University Hospital Giessen, Giessen, Germany., Michels B; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Korell F; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany., Ho AD; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany., Müller-Tidow C; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany., Schmitt M; Internal Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany.; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ)/National Center for Tumor Diseases (NCT), Heidelberg, Germany.

Publikováno v: Leukemia [Leukemia] 2024 Nov; Vol. 38 (11), pp. 2419-2428. Date of Electronic Publication: 2024 Aug 27.

Antibiotic-induced loss of gut microbiome metabolic output correlates with clinical responses to CAR T-cell therapy.

Autor: Prasad R; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Rehman A; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Rehman L; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Darbaniyan F; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Blumenberg V; University Hospital, LMU Munich, Germany., Schubert ML; University Clinic Heidelberg, Germany., Mor U; Weizmann Institute of Science, Rehovot, Israel., Zamir E; German Cancer Research Center (DKFZ), Heidelberg, Germany., Schmidt S; German Cancer Research Center (DKFZ), Heidelberg, Germany., Hayase T; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Chia-Chi C; The University of Texas MD Anderson Cancer Center, United States., McDaniel LK; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Flores I; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Strati P; The University of Texas MD Anderson Cancer Center, United States., Nair R; The University of Texas MD Anderson Cancer Center, United States., Chihara D; The University of Texas MD Anderson Cancer Center, United States., Fayad LE; University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States., Ahmed S; The University of Texas MD Anderson Cancer Center, United States., Iyer SP; The University of Texas MD Anderson Cancer Center, United States., Wang ML; The University of Texas MD Anderson Cancer Center, United States., Jain P; The University of Texas MD Anderson Cancer Center, United States., Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Westin JR; The University of Texas MD Anderson Cancer Center, United States., Arora R; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Turner JG; Moffitt Cancer Center, Tampa, Florida, United States., Khawaja F; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Wu R; The University of Texas MD Anderson Cancer Center, United States., Dennison JB; The University of Texas MD Anderson Cancer Center, United States., Menges M; Moffitt Cancer Center, Tampa, Florida, United States., Hidalgo-Vargas M; Moffitt Cancer Center, Tampa, Florida, United States., Reid KM; Moffitt Cancer Center, Tampa, Florida, United States., Davila ML; Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States., Dreger P; University Clinic Heidelberg, Heidelberg, Germany., Korell F; University Hospital Heidelberg, Heidelberg, Germany., Schmitt A; University Clinic Heidelberg, Germany., Tanner MR; The University of Texas MD Anderson Cancer Center, United States., Champlin RE; The University of Texas MD Anderson Cancer Center, United States., Flowers CR; The University of Texas MD Anderson Cancer Center, United States., Shpall EJ; The University of Texas MD Anderson Cancer Center, United States., Hanash S; The University of Texas MD Anderson Cancer Center, United States., Neelapu SS; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States., Schmitt M; University Clinic Heidelberg, Germany., Subklewe M; University Hospital, LMU Munich, Munich, Germany., Fahrmann J; The University of Texas MD Anderson Cancer Center, United States., Stein-Thoeringer C; University of Tuebingen, Tuebingen, Germany., Elinav E; Weizmann Institute of Science, Rehovot, Israel., Jain MD; Moffitt Cancer Center, Tampa, Florida, United States., Hayase E; The University of Texas MD Anderson Cancer Center, United States., Jenq RR; The University of Texas MD Anderson Cancer Center, United States., Saini NY; The University of Texas MD Anderson Cancer Center, Houston, Texas, United States.

Publikováno v: Blood [Blood] 2024 Oct 23. Date of Electronic Publication: 2024 Oct 23.

Analysis of Symptoms of COVID-19 Positive Patients and Potential Effects on Initial Assessment

Autor: Korell F, Giannitsis E, Merle U, Kihm LP

Publikováno v: Open Access Emergency Medicine, Vol Volume 12, Pp 451-457 (2020)

Felix Korell,1,2 Evangelos Giannitsis,3 Uta Merle,4 Lars Philipp Kihm1,5 1Casualty Department, University Hospital Heidelberg, Heidelberg, Germany; 2Department of Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany; 3Department o

Externí odkaz: https://doaj.org/article/52fefb1c789f41c68647bb15be9e88f9

Comparative analysis of Bcl-2 family protein overexpression in CAR T cells alone and in combination with BH3 mimetics.

Autor: Korell F; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.; Harvard Medical School, Boston, MA 02115, USA.; Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02142, USA., Olson ML; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Salas-Benito D; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.; Harvard Medical School, Boston, MA 02115, USA., Leick MB; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.; Harvard Medical School, Boston, MA 02115, USA., Larson RC; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.; Harvard Medical School, Boston, MA 02115, USA.; Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02142, USA., Bouffard A; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA., Silva H; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA., Gasparetto A; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA., Berger TR; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA., Kann MC; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA., Mergen M; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA., Kienka T; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.; Harvard Medical School, Boston, MA 02115, USA.; Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02142, USA., Wehrli M; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.; Harvard Medical School, Boston, MA 02115, USA., Haradhvala NJ; Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02142, USA., Bailey SR; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.; Harvard Medical School, Boston, MA 02115, USA., Letai A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA., Maus MV; Cellular Immunotherapy Program, Massachusetts General Hospital Cancer Center, Charlestown, MA 02129, USA.; Harvard Medical School, Boston, MA 02115, USA.; Broad Institute of Harvard University and Massachusetts Institute of Technology, Cambridge, MA 02142, USA.

Publikováno v: Science translational medicine [Sci Transl Med] 2024 Jun 05; Vol. 16 (750), pp. eadk7640. Date of Electronic Publication: 2024 Jun 05.

Mesothelin CAR T Cells Secreting Anti-FAP/Anti-CD3 Molecules Efficiently Target Pancreatic Adenocarcinoma and its Stroma.

Autor: Wehrli M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Guinn S; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Cancer Convergence Institute and Bloomberg Kimmel Institute at Johns Hopkins, University, Baltimore, Maryland., Birocchi F; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Kuo A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Sun Y; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Larson RC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Almazan AJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Scarfò I; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Bouffard AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Bailey SR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Anekal PV; MicRoN Core, Harvard Medical School, Boston, Massachusetts., Montero Llopis P; MicRoN Core, Harvard Medical School, Boston, Massachusetts., Nieman LT; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Song Y; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Xu KH; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Berger TR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Kann MC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Silva H; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Salas-Benito D; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Kienka T; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Grauwet K; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Armstrong TD; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Cancer Convergence Institute and Bloomberg Kimmel Institute at Johns Hopkins, University, Baltimore, Maryland., Zhang R; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Cancer Convergence Institute and Bloomberg Kimmel Institute at Johns Hopkins, University, Baltimore, Maryland., Zhu Q; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Cancer Convergence Institute and Bloomberg Kimmel Institute at Johns Hopkins, University, Baltimore, Maryland., Fu J; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Cancer Convergence Institute and Bloomberg Kimmel Institute at Johns Hopkins, University, Baltimore, Maryland., Schmidts A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Korell F; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Jan M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Choi BD; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Liss AS; Division of Gastrointestinal and Oncologic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Boland GM; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Department of Surgery, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Ting DT; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Burkhart RA; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Cancer Convergence Institute and Bloomberg Kimmel Institute at Johns Hopkins, University, Baltimore, Maryland., Jenkins RW; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts., Zheng L; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Cancer Convergence Institute and Bloomberg Kimmel Institute at Johns Hopkins, University, Baltimore, Maryland., Jaffee EM; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Cancer Convergence Institute and Bloomberg Kimmel Institute at Johns Hopkins, University, Baltimore, Maryland., Zimmerman JW; Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.; Cancer Convergence Institute and Bloomberg Kimmel Institute at Johns Hopkins, University, Baltimore, Maryland., Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Cancer Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.; Blood and Marrow Transplant Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 May 01; Vol. 30 (9), pp. 1859-1877.